8ALX

Structure of human PD-L1 in complex with inhibitor

8ALX の概要

• エントリーDOI: 10.2210/pdb8alx/pdb
• 分子名称: Programmed cell death 1 ligand 1, 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.]PYRAZOLE, AMINOMETHYLAMIDE, ACETATE ION, ... (5 entities in total)
• 機能のキーワード: pd-l1, immunooncology, immune system
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 16944.29

構造登録者

Rodriguez, I.,Grudnik, P.,Holak, T.,Magiera-Mularz, K. (登録日: 2022-08-01, 公開日: 2023-08-16, 最終更新日: 2024-07-10)

主引用文献

Rodriguez, I.,Kocik-Krol, J.,Skalniak, L.,Musielak, B.,Wisniewska, A.,Ciesiolkiewicz, A.,Berlicki, L.,Plewka, J.,Grudnik, P.,Stec, M.,Siedlar, M.,Holak, T.A.,Magiera-Mularz, K.
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies.
Mol Cancer, 22:150-150, 2023

PubMed Abstract: Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway continues to lead to the testing of multiple approaches and optimizations. Recently, a series of macrocyclic peptides have been developed that exhibit binding strengths to PD-L1 ranging from sub-micromolar to micromolar. In this study, we present the most potent non-antibody-based PD-1/PD-L1 interaction inhibitor reported to date. The structural and biological characterization of this macrocyclic PD-L1 targeting peptide provides the rationale for inhibition of both PD-1/PD-L1 and CD80/PD-L1 complexes. The IC and EC values obtained in PD-L1 binding assays indicate that the pAC65 peptide has potency equivalent to the current FDA-approved mAbs and may have similar activity to the BMS986189 peptide, which entered the clinical trial and has favorable safety and pharmacokinetic data. The data presented here delineate the generation of similar peptides with improved biological activities and applications not only in the field of cancer immunotherapy but also in other disorders related to the immune system.

PubMed: 37679783
DOI: 10.1186/s12943-023-01853-4

実験手法

X-RAY DIFFRACTION (1.1 Å)